DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Sinovac, Pandemic Influenza A/H1N1 Vaccine in 6 to 35 Months Infants

Information source: Sinovac Biotech Co., Ltd
ClinicalTrials.gov processed this data on August 20, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Influenza

Intervention: Pandemic influenza A/H1N1 vaccine (Biological); Pandemic influenza A/H1N1 vaccine (Biological); Seasonal trivalent vaccine (Biological)

Phase: Phase 4

Status: Completed

Sponsored by: Sinovac Biotech Co., Ltd


A single center, observer-masked, randomized clinical trial is to be conducted in 6-35 months infants to evaluate the safety and immunogenicity of Sinovac's influenza A/H1N1 Vaccine (PANFLU. 1).

Clinical Details

Official title: A Blinded, Randomized and Controlled Clinical Trial With Influenza A/H1N1 Split-virion Vaccine in 6 to 35 Months Infants

Study design: Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Prevention

Primary outcome: Evaluate immunogenicity of H1N1 vaccine with seasonal influenza vaccine in infants

Secondary outcome: Evaluate safety of H1N1 vaccine with seasonal influenza vaccine in infants


Minimum age: 6 Months. Maximum age: 35 Months. Gender(s): Both.


Inclusion Criteria: 1. Healthy male or female aged between 6 and 35 months 2. Full-term birth, birth weight 2,500 grams or more 3. provided birth certification or vaccination card Parent(s) or legal guardian(s) are able to understand and sign the informed consent Exclusion Criteria: 1. Cases, cured cases and close contact of influenza A (H1N1) virus 2. Subject that has a medical history of any of the following: allergic history, or allergic to any ingredient of vaccine, such as egg, egg protein, etc 3. Serious adverse reactions to vaccines such as anaphylaxis, hives, respiratory difficulty, angioedema, or abdominal pain 4. Symptoms of acute infection within a week 5. Autoimmune disease or immunodeficiency 6. Congenital malformation, developmental disorders or serious chronic diseases (such as Down's syndrome, diabetes, sickle cell anemia or neurological disorders) 7. Asthma that is unstable or required emergent care, hospitalization or intubation during the past two years or that required the use of oral or intravenous corticosteroids 8. Bleeding disorder diagnosed by a doctor (e. g. factor deficiency, coagulopathy, or platelet disorder requiring special precautions) or significant bruising or bleeding difficulties with IM injections or blood draws 9. History or family history of convulsions, epilepsy, brain disease and psychiatric 10. Asplenia, functional asplenia or any condition resulting in the absence or removal o the spleen 11. Guillain-Barre Syndrome 12. Administration of 2009-2010 seasonal vaccine 13. History of any blood products within 3 months 14. Administration of any other investigational research agents within 30 days 15. Administration of any live attenuated vaccine within 30 days 16. Administration of subunit or inactivated vaccines within 14 days 17. Be receiving anti-TB prophylaxis or therapy currently 18. Axillary temperature > 37. 0 centigrade at the time of dosing 19. Any medical, psychiatric, social condition, occupational reason or other responsibility that, in the judgment of the investigator, is a contraindication to protocol participation or impairs a volunteer's ability to give informed consent

Locations and Contacts

GuangXi Center for Diseases Control and Prevention, Guilin, Guangxi, China
Additional Information

Starting date: December 2009
Last updated: March 13, 2013

Page last updated: August 20, 2015

-- advertisement -- The American Red Cross
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017